Economic burden of central nervous system metastases in human epidermal growth factor receptor 2-positive breast cancer.
Future Oncol
; 17(26): 3457-3463, 2021 Sep.
Article
en En
| MEDLINE
| ID: mdl-34044579
ABSTRACT
Aim:
Compare healthcare resource utilization and costs among patients with HER2+ metastatic breast cancer (MBC) with and without central nervous system (CNS) metastases.Methods:
Retrospective matched cohort study using IQVIA's PharMetrics® Plus claims database.Results:
Patients with CNS metastases (n = 753) experienced more outpatient, emergency room and inpatient visits versus controls (n = 753; all p < 0.05). In the post-index year, median total all-cause healthcare costs were significantly higher among patients with CNS metastases versus controls ($112,402 vs $50,835; p < 0.0001); outpatient costs primarily drove the cost differential.Conclusion:
More effective therapies are needed that improve clinical outcomes and reduce economic burden associated with CNS metastases in patients with HER2+ MBC.Palabras clave
Texto completo:
1
Bases de datos:
MEDLINE
Asunto principal:
Neoplasias de la Mama
/
Bases de Datos Factuales
/
Costos de la Atención en Salud
/
Neoplasias del Sistema Nervioso Central
/
Receptor ErbB-2
/
Estrés Financiero
Tipo de estudio:
Health_economic_evaluation
/
Observational_studies
/
Prognostic_studies
/
Risk_factors_studies
Límite:
Female
/
Humans
/
Middle aged
Idioma:
En
Revista:
Future Oncol
Año:
2021
Tipo del documento:
Article
País de afiliación:
Estados Unidos